{
    "clinical_study": {
        "@rank": "62291", 
        "arm_group": {
            "arm_group_label": "Arm I", 
            "arm_group_type": "Experimental", 
            "description": "Beginning on day 1, patients receive topotecan IV continuously for 3-6 weeks and thoracic radiotherapy 5 days a week for 2, 3, or 6 weeks. Cohorts of 4-6 patients receive escalating doses of topotecan and thoracic radiotherapy until the maximum tolerated dose (MTD) of each therapy is determined. The MTD is defined as the dose preceding that at which 2 of 4 or 6 patients experience dose-limiting toxicity. Six additional patients are treated at the MTD. Patients who fail to achieve complete remission (CR) and continue to have measurable disease at 4-6 weeks after completion of radiotherapy receive topotecan IV continuously on days 1-21 at 1 dose level preceding the MTD as determined by the ongoing Protocol NYU-9123. Treatment continues every 4 weeks in the absence of unacceptable toxicity."
        }, 
        "brief_summary": {
            "textblock": "Phase I trial to study the effectiveness of radiation therapy plus topotecan in treating\n      patients who have non-small cell lung cancer. Drugs used in chemotherapy use different ways\n      to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy and\n      radiation therapy may kill more tumor cells."
        }, 
        "brief_title": "Radiation Therapy Plus Topotecan in Treating Patients With Non-small Cell Lung Cancer", 
        "condition": "Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n      I. Determine the maximum tolerated dose of topotecan and chest irradiation in patients with\n      non-small cell lung cancer.\n\n      II. Determine the qualitative and quantitative toxic effects of this regimen in these\n      patients.\n\n      III. Determine the degree of antitumor activity of this regimen in these patients.\n\n      OUTLINE: This is a dose escalation study of topotecan and thoracic radiotherapy.\n\n      Beginning on day 1, patients receive topotecan IV continuously for 3-6 weeks and thoracic\n      radiotherapy 5 days a week for 2, 3, or 6 weeks. Cohorts of 4-6 patients receive escalating\n      doses of topotecan and thoracic radiotherapy until the maximum tolerated dose (MTD) of each\n      therapy is determined. The MTD is defined as the dose preceding that at which 2 of 4 or 6\n      patients experience dose-limiting toxicity. Six additional patients are treated at the MTD.\n      Patients who fail to achieve complete remission (CR) and continue to have measurable disease\n      at 4-6 weeks after completion of radiotherapy receive topotecan IV continuously on days 1-21\n      at 1 dose level preceding the MTD as determined by the ongoing Protocol NYU-9123. Treatment\n      continues every 4 weeks in the absence of unacceptable toxicity."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically proven non-small cell lung cancer\n\n          -  Eligible for chest irradiation with 3,000 to 6,000 cGy (based upon standard\n             radiotherapy indications)\n\n          -  Measurable or evaluable disease\n\n          -  Measurable disease defined as bidimensionally measurable lesion on physical exam or\n             radiograph (CT or MRI acceptable)\n\n        PATIENT CHARACTERISTICS:\n\n          -  Age: 18 and over\n\n          -  Performance status: 0-2\n\n          -  Life expectancy: At least 12 weeks\n\n          -  WBC at least 4,000/mm3\n\n          -  Platelet count at least 100,000/mm3\n\n          -  Bilirubin no greater than 1.5 mg/dL\n\n          -  AST less than 3 times normal\n\n          -  Alkaline phosphatase less than 3 times normal\n\n          -  Creatinine no greater than 1.5 mg/dL\n\n          -  Not pregnant or nursing\n\n        PRIOR CONCURRENT THERAPY:\n\n          -  No more than 1 prior chemotherapy regimen allowed\n\n          -  At least 4 weeks since prior chemotherapy and recovered\n\n          -  No prior radiotherapy\n\n          -  Recovered from toxic effects of any prior therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 1, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002537", 
            "org_study_id": "NCI-2012-02487", 
            "secondary_id": [
                "NYU-9301", 
                "NCI-T93-0015D", 
                "CDR0000078480"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm I", 
                "intervention_name": "topotecan hydrochloride", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm I", 
                "intervention_name": "radiation therapy", 
                "intervention_type": "Radiation"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Topotecan"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "recurrent non-small cell lung cancer", 
            "stage IIIA non-small cell lung cancer", 
            "stage IIIB non-small cell lung cancer", 
            "stage IV non-small cell lung cancer"
        ], 
        "lastchanged_date": "February 8, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/NYU-9301"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10016"
                }, 
                "name": "NYU School of Medicine's Kaplan Comprehensive Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A PHASE I STUDY OF PROLONGED LOW-DOSE TOPOTECAN INFUSION COMBINED WITH CHEST IRRADIATION", 
        "overall_official": {
            "affiliation": "New York University School of Medicine", 
            "last_name": "Howard S. Hochster, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2006", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002537"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "September 1993", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2006"
    }, 
    "geocoordinates": {
        "NYU School of Medicine's Kaplan Comprehensive Cancer Center": "40.714 -74.006"
    }
}